SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that it has been awarded a European patent for its Optical Biopsy System for Tissue Diagnosis.
Jim Hitchin, SpectraScience's CEO, commented, "This patent is important to the Company's optical biopsy technology because it provides protection in the areas of tissue surveillance, characterization, diagnosis and treatment. It supports the Company's fundamental technology of non-invasive, low-level laser diagnosis of pre-cancerous and cancerous tissue. This is another key patent in our expanding intellectual property portfolio that underscores our commitment at SpectraScience to develop better, more reliable cancer screening technologies."
Hitchin added, "Accurate imaging is critical to earlier and more effective identification of normal, pre-cancerous and/or cancerous tissue, and this invention provides methods of making our screening devices more useful to the physician and, more importantly, to the patient."
SpectraScience holds approximately 60 patents worldwide that have been issued or are pending on its WavSTAT(R) Optical Biopsy and LUMA(R) Cervical Imaging Systems. These devices are used to diagnose tissue quickly to determine if it is normal, pre-cancerous, or cancerous. The WavSTAT and LUMA Systems are currently approved by the FDA for detecting pre-cancerous and cancerous tissue in the colon and cervix, respectively. An evaluation of the WavSTAT for detection of pre-cancers in the throat ("Barrett's esophagus") is being tested.
This news release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. These forward-looking
statements involve risks and uncertainties that may cause SpectraScience's
|SOURCE SpectraScience, Inc.|
Copyright©2008 PR Newswire.
All rights reserved